Publications by authors named "Louis Sloan"

Claim this Profile
T
Tropism Switching Is Rare in Aviremic HIV-Infected Patients Virologically Suppressed With Non-Entry-Inhibiting Antiretroviral Regimens.
Louis M Sloan, Mezgebe G Berhe, Anna Ursales, Bryan King, John E Fuchs

Ann Pharmacother· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Louis Sloan

Lancet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.
Yves Lévy, Rodolphe Thiébaut, Monica Montes, Christine Lacabaratz, Louis Sloan

Eur J Immunol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and morphologic findings in disseminated Scedosporium apiospermum infections in immunocompromised patients.
Molly M Campa-Thompson, James A West, Joseph M Guileyardo, Cedric W Spak, Louis M Sloan

Proc (Bayl Univ Med Cent)· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.
Anne-Laure Flamar, Yaming Xue, Sandra M Zurawski, Monica Montes, Bryan King, Louis Sloan

AIDS· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herpes simplex virus meningitis complicated by ascending paralysis.
Mina M Benjamin, Kyle L Gummelt, Rabeea Zaki, Aasim Afzal, Louis Sloan

Proc (Bayl Univ Med Cent)· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Princy Kumar, Edwin DeJesus, Gregory Huhn, Louis Sloan, Catherine Butkus Small

BMC Infect Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Benjamin Young, Kathleen E Squires, Lisa L Ross, Lizette Santiago, Louis M Sloan

AIDS Res Hum Retroviruses· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Sherene Min, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy

AIDS· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
Amanda Cobb, Lee K Roberts, A Karolina Palucka, Holly Mead, Monica Montes, Louis Sloan

J Immunol Methods· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system tuberculosis.
Vincent C Kuo, Louis M Sloan, Michael Emmett

Proc (Bayl Univ Med Cent)· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
Juan González-García, Daniel Cohen, Margaret Johnson, Louis Sloan, Linda Fredrick

AIDS Res Hum Retroviruses· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Kimberly Y Smith, Parul Patel, Derek Fine, Nicholaos Bellos, Louis Sloan

AIDS· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Edwin Dejesus, Benjamin Young, Javier O Morales-Ramirez, Louis Sloan, Douglas J Ward

J Acquir Immune Defic Syndr· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Charles B Hicks, Edwin DeJesus, Louis M Sloan, Michael G Sension, David A Wohl

AIDS Res Hum Retroviruses· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary effusion lymphoma diagnosed by pericardiocentesis.
Michael C Nemunaitis, Jeffrey M Schussler, S Michelle Shiller, Louis M Sloan, Robert G Mennel

Proc (Bayl Univ Med Cent)· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Judith Currier, Adriano Lazzarin, Louis Sloan, Nathan Clumeck, Jihad Slims

Antivir Ther· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
Allan Rodriguez, Christina Hill-Zabala, Louis Sloan, Thomas Jefferson, Linda Yau

J Acquir Immune Defic Syndr· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis